Abstract
Deletions in the short arm of chromosome 12 are the rarest subtelomeric imbalances. Less than 20 patients have been reported to date, and their microdeletions were identified either by FISH or array-CGH without SNP data. Here, we report a patient with a 12p13.32pter mosaic deletion detected by chromosome microarray analysis with loss of heterozygosity (LOH) of the deleted segment in addition to the adjacent distal segment. LOH is indicative of a complex rearrangement, suggestive of mitotic microhomology-mediated break-induced replication.
References
1.
Abdelmoity AT, Hall JJ, Bittel DC, Yu S: 1.39 Mb inherited interstitial deletion in 12p13.33 associated with developmental delay. Eur J Med Genet 54:198-203 (2011).
2.
Baker E, Hinton L, Callen DF, Haan EA, Dobbie A, Sutherland GR: A familial cryptic subtelomeric deletion 12p with variable phenotypic effect. Clin Genet 61:198-201 (2002).
3.
Hastings PJ, Lupski JR, Rosenberg SM, Ira G: Mechanisms of change in gene copy number. Nat Rev Genet 10:551-566 (2009).
4.
MacDonald AH, Rodríguez L, Aceña I, Martínez-Fernandez ML, Sanchez-Izquierdo D, et al: Subtelomeric deletion of 12p: description of a third case and review. Am J Med Genet 152A:1561-1566 (2010).
5.
Magnelli NC, Therman E: Partial 12p deletion: a cause for a mental retardation, multiple congenital abnormality syndrome. J Med Genet 12:105-108 (1975).
6.
Martin MM, Vanzo RJ, Sdano MR, Baxter AL, South ST: Mosaic deletion of 20pter due to rescue by somatic recombination. Am J Med Genet 170:243-248 (2016).
7.
Mayeda K, Weiss L, Lindahl R, Dully M: Localization of the human lactate dehydrogenase B gene on the short arm of chromosome 12. Am J Hum Genet 26:59-64 (1974).
8.
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764 (2007).
9.
Ravnan JB, Tepperberg JH, Papenhausen P, Lamb AN, Hedrik J, et al: Subtelomere FISH analysis of 11 688 cases: an evaluation of the frequency and pattern of subtelomere rearrangements in individuals with developmental disabilities. J Med Genet 43:478-489 (2006).
10.
Romain DR, Goldsmith J, Columbano-Green LM, Chapman CJ, Smythe RH, Parfitt RG: Partial monosomy 12p13.1-13.3. J Med Genet 24:434-436 (1987).
11.
Rooryck C, Stef M, Burgelin I, Simon D, Souakri N, et al: 2.3 Mb terminal deletion in 12p13.33 associated with oculoauriculovertebral spectrum and evaluation of WNT5B as a candidate gene. Eur J Med Genet 52:446-449 (2009).
12.
Rosenberg C, Janson M, Nordeskjold M, Borresen AL, Vianna-Morgante AM: Intragenic reorganization of RB1 in a complex (4;13) rearrangement demonstrated by FISH. Cytogenet Cell Genet 65:268-271 (1994).
13.
Sahoo T, Wang JC, Elnaggar MM, Sanches-Lara P, Ross LP, et al: Concurrent triplication and uniparental isodisomy: evidence for microhomology-mediated break-induced replication model for genomic rearrangements. Eur J Hum Genet 23:61-66 (2015).
14.
Silva IM, Rosenfeld J, Antoniuk SA, Raskin S, Sotomaior VS: A 1.5Mb terminal deletion of 12p associated with autism spectrum disorder. Gene 542:83-86 (2014).
15.
Thevenon J, Callier P, Andrieux J, Delobel B, David A, et al: 12p13.33 microdeletion including ELKS/ERC1, a new locus associated with childhood apraxia of speech. Eur J Hum Genet 21:82-88 (2013).
16.
Vargas H, Beldia G, Korosh W, Sudhalter V, Iqbal A, et al: A 4.5 Mb terminal deletion of chromosome 12p helps further define a psychosis-associated locus. Eur J Med Genet 55:573-576 (2012).
17.
Zhang F, Carvalho CM, Lupski JR: Complex human chromosomal and genomic rearrangements. Trends Genet 25:298-307 (2009).
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.